Sakubitril/walsartan dla pacjenta z ostrą niewydolnością serca z obniżoną frakcją wyrzutową lewej komory w okresie przedwypisowym — im wcześniej, tym lepiej

Abstract

Based on results of trials TRANSITION and PIONIEER-HF the Heart Failure Association of the European Society of Cardiology reported an expert consensus 2019 that the initiation of sacubitril/valsartan rather than an angiotensin-converting enzyme (ACE) inhibitors or an angiotensin II type 1 receptor blocker may be considered for patients hospitalized with new-onset heart failure with reduced ejection fraction (HFrEF) or decompensated chronic HFrEF to reduce the short-term risk of adverse events and to simplify management by avoiding the need to titrate ACE inhibitors first and then switch to angiotensin receptor neprilysin inhibitor (ARNI). The paper described the new data from the two trials TRANSITION and PIONIEER-HF.